title: Clinicopathological analysis and risk factors of advanced colorectal neoplasms incidentally detected by 18F-FDG PET-CT.
abstract: BACKGROUND
  As the clinical use of fluorine-18-fluorodeoxyglucose PET-computed tomography (F-FDG PET-CT) has increased, the incidental finding of F-FDG uptake with subsequent diagnosis of advanced neoplasm at colorectum has increased. The aim of this study is to analyze the characteristics and risk factors of advanced colorectal neoplasm incidentally detected by F-FDG PET-CT.
  
  
  METHODS
  Patients who underwent colonoscopy because of an incidental finding of F-FDG uptake at the colorectum from January 2006 to January 2015 at Yeungnam University Hospital were reviewed retrospectively. Advanced neoplasm was defined as adenoma of at least 10 mm, adenoma with serrated or villous component, high-grade dysplasia, and adenocarcinoma.
  
  
  RESULTS
  Of the 19 798 candidates, 180 patients with incidental colorectal F-FDG uptake were included in this study. The indications of PET-CT were metastasis work-up, health screening, and others. The male to female ratio was 1.6 : 1 and the mean age was 62.7±11.4 years. A total of 156 lesions were detected in the colorectum and 86 (47.8%) were diagnosed as advanced neoplasms. Of the 86 patients with advanced neoplasms, 34 (39.5%) underwent an operation, 34 (39.5%) underwent endoscopic resection, and 18 (20.9%) underwent chemotherapy or conservative treatments. In univariate analysis, age of 62.5 years or older, carcinoembryonic antigen (CEA) of at least 3.4 ng/ml, maximum standardized uptake value (SUVmax) of at least 8.0, hypertension, F-FDG uptake on the rectosigmoid, and PET-CT for metastasis work-up showed a significant association with advanced neoplasm. In multivariate analysis, CEA (P=0.028), SUVmax (P<0.001) and an indication of PET-CT for metastasis work-up (P=0.008) were independent predictors of advanced neoplasm.
  
  
  CONCLUSIONS
  Colonoscopy should be recommended in case of F-FDG uptake at the colorectum, particularly in patients with CEA of at least 3.4 ng/ml, SUVmax of at least 8.0, or metastasis work-up of malignancy.
authors.affiliation: aDepartment of Internal Medicine, Division of Gastroenterology and Hepatology bDepartment of Nuclear Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.
authors.forename: Seung Min
authors.initials: SM
authors.lastname: Chung
authors.forename: Kyeong Ok
authors.initials: KO
authors.lastname: Kim
authors.forename: Ihn Ho
authors.initials: IH
authors.lastname: Cho
authors.forename: Tae Nyeun
authors.initials: TN
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D033162:Incidental Findings; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods; D012372:ROC Curve; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18